BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 21664646)

  • 1. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
    Karamitopoulou E; Zlobec I; Panayiotides I; Patsouris ES; Peros G; Rallis G; Lapas C; Karakitsos P; Terracciano LM; Lugli A
    Hum Pathol; 2011 Dec; 42(12):1888-96. PubMed ID: 21664646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
    Karamitopoulou E; Zlobec I; Koumarianou A; Patsouris ES; Peros G; Lugli A
    Cancer; 2010 Oct; 116(19):4474-86. PubMed ID: 20572035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
    Zlobec I; Baker K; Minoo P; Jass JR; Terracciano L; Lugli A
    Clin Cancer Res; 2008 Jan; 14(1):143-8. PubMed ID: 18172264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis.
    Zlobec I; Baker K; Terracciano LM; Lugli A
    Clin Cancer Res; 2008 Jun; 14(12):3798-806. PubMed ID: 18559599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.
    Zlobec I; Terracciano L; Tornillo L; Günthert U; Vuong T; Jass JR; Lugli A
    Gut; 2008 Oct; 57(10):1413-9. PubMed ID: 18436576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients.
    Al-Mulla F; Hagan S; Behbehani AI; Bitar MS; George SS; Going JJ; García JJ; Scott L; Fyfe N; Murray GI; Kolch W
    J Clin Oncol; 2006 Dec; 24(36):5672-9. PubMed ID: 17179102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.
    Paik SS; Jang KS; Song YS; Jang SH; Min KW; Han HX; Na W; Lee KH; Choi D; Jang SJ
    Ann Surg Oncol; 2007 Dec; 14(12):3453-9. PubMed ID: 17882496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of TWEAK expression in colorectal cancer and effect of its inhibition on invasion.
    Lin BR; Huang MT; Chen ST; Jeng YM; Li YJ; Liang JT; Lee PH; Chang KJ; Chang CC
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S385-94. PubMed ID: 21681381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
    Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
    J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.
    Kahlert C; Lahes S; Radhakrishnan P; Dutta S; Mogler C; Herpel E; Brand K; Steinert G; Schneider M; Mollenhauer M; Reissfelder C; Klupp F; Fritzmann J; Wunder C; Benner A; Kloor M; Huth C; Contin P; Ulrich A; Koch M; Weitz J
    Clin Cancer Res; 2011 Dec; 17(24):7654-63. PubMed ID: 22042972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach.
    Lugli A; Zlobec I; Minoo P; Baker K; Tornillo L; Terracciano L; Jass JR
    Hum Pathol; 2006 Aug; 37(8):1022-31. PubMed ID: 16867865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of matrix metalloproteinase-7 mRNA expression in the invasive front and inner surface of tumor tissues in patients with colorectal cancer.
    Higashiguchi T; Hotta T; Takifuji K; Yokoyama S; Matsuda K; Tominaga T; Oku Y; Yamaue H
    Dis Colon Rectum; 2007 Oct; 50(10):1585-93. PubMed ID: 17676380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer.
    Boo YJ; Park JM; Kim J; Chae YS; Min BW; Um JW; Moon HY
    Ann Surg Oncol; 2007 May; 14(5):1703-11. PubMed ID: 17211730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
    Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
    Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of WNT pathway in surgically-treated colorectal cancer: β-catenin expression predicts for disease-free survival.
    Kamposioras K; Konstantara A; Kotoula V; Lakis S; Kouvatseas G; Akriviadis E; Vrettou E; Dionysopoulos D; Krikelis D; Papadopoulou K; Charalambous E; Chrisafi S; Konstantaras C; Fountzilas G
    Anticancer Res; 2013 Oct; 33(10):4573-84. PubMed ID: 24123033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor.
    Tamura M; Oda M; Tsunezuka Y; Matsumoto I; Kawakami K; Watanabe G
    J Thorac Cardiovasc Surg; 2004 Oct; 128(4):517-22. PubMed ID: 15457151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival.
    Yoo PS; Sullivan CA; Kiang S; Gao W; Uchio EM; Chung GG; Cha CH
    Ann Surg Oncol; 2009 Jan; 16(1):200-7. PubMed ID: 19009247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study.
    Dong P; Li X; Yu Z; Lu G
    J Laryngol Otol; 2007 Dec; 121(12):1177-83. PubMed ID: 17888194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
    Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H
    Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.